Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000049.xml
Download PDF
Clin Colon Rectal Surg
DOI: 10.1055/a-2760-7712
DOI: 10.1055/a-2760-7712
Review Article
Navigating Shared Decision-Making in Non-Operative Management of Locally Advanced Rectal Cancer
Authors
Funding Information This research was funded by T32 National Institute of Health, award number T32TR004418.
Abstract
The management of locally advanced rectal cancer has evolved significantly with the introduction of total neoadjuvant therapy, which increases rates of clinical complete response and enables select patients to pursue non-operative management through a watch-and-wait strategy. While total mesorectal excision remains the standard curative approach, it is associated with considerable morbidity and long-term impacts on bowel, urinary, and sexual function. In contrast, non-operative management offers organ preservation and improved functional outcomes but carries oncologic uncertainty and requires intensive surveillance. This review examines the comparative benefits and limitations of total mesorectal excision and non-operative management, highlighting their impact on quality of life, recurrence risk, and patient-centered care. It also explores emerging strategies to support shared decision-making, including decision aids and predictive modeling, including risk preference assessments. These tools are essential to support informed, individualized decisions and to promote ethically grounded, evidence-based care in the evolving landscape of rectal cancer management.
Keywords
locally advanced rectal cancer - rectal cancer - shared decision-making - non-operative management - watch-and-waitPublication History
Article published online:
23 December 2025
© 2025. Thieme. All rights reserved.
Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
-
References
- 1 Gaetani RS, Ladin K, Abelson JS. Journey through the decades: The evolution in treatment and shared decision making for locally advanced rectal cancer. Cancers (Basel) 2024; 16 (16) 2807
- 2 Smith CA, Kachnic LA. Evolving treatment paradigm in the treatment of locally advanced rectal cancer. J Natl Compr Canc Netw 2018; 16 (07) 909-915
- 3 Kapiteijn E, Marijnen CA, Nagtegaal ID. et al; Dutch Colorectal Cancer Group. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001; 345 (09) 638-646
- 4 Chessin DB, Enker W, Cohen AM. et al. Complications after preoperative combined modality therapy and radical resection of locally advanced rectal cancer: A 14-year experience from a specialty service. J Am Coll Surg 2005; 200 (06) 876-882 , discussion 882–884
- 5 Saravanabavan S, Kazi M, Murugan J. et al. Outcomes of extended total mesorectal excision in patients with locally advanced rectal cancer. Colorectal Dis 2023; 25 (07) 1423-1432
- 6 Benson AB, Venook AP, Al-Hawary MM. et al. Rectal cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2022; 20 (10) 1139-1167
- 7 Garcia-Aguilar J, Patil S, Gollub MJ. et al. Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy. J Clin Oncol 2022; 40 (23) 2546-2556
- 8 Williams H, Fokas E, Diefenhardt M. et al; German Rectal Cancer Study Group, OPRA Consortium. Survival among patients treated with total mesorectal excision or selective watch-and-wait after total neoadjuvant therapy: A pooled analysis of the CAO/ARO/AIO-12 and OPRA randomized phase II trials. Ann Oncol 2025; 36 (05) 543-547
- 9 Verheij FS, Omer DM, Williams H. et al. Long-term results of organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy: The Randomized Phase II OPRA trial. J Clin Oncol 2024; 42 (05) 500-506
- 10 Habr-Gama A, Gama-Rodrigues J, São Julião GP. et al. Local recurrence after complete clinical response and watch and wait in rectal cancer after neoadjuvant chemoradiation: Impact of salvage therapy on local disease control. Int J Radiat Oncol Biol Phys 2014; 88 (04) 822-828
- 11 Martens MH, Maas M, Heijnen LA. et al. Long-term outcome of an organ preservation program after neoadjuvant treatment for rectal cancer. J Natl Cancer Inst 2016; 108 (12) djw171
- 12 Langenfeld SJ, Davis BR, Vogel JD. et al; Clinical Practice Guidelines Committee of the American Society of Colon and Rectal Surgeons. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Rectal Cancer 2023 Supplement. Dis Colon Rectum 2024; 67 (01) 18-31
- 13 American College of Surgeons, NAPRC Standards and Resources. Accessed April 3, 2025 at: https://www.facs.org/quality-programs/cancer-programs/national-accreditation-program-for-rectal-cancer/standards-and-resources/
- 14 Gunderson LL, Jessup JM, Sargent DJ, Greene FL, Stewart A. Revised tumor and node categorization for rectal cancer based on surveillance, epidemiology, and end results and rectal pooled analysis outcomes. J Clin Oncol 2010; 28 (02) 256-263
- 15 Knol J, Keller DS. Total mesorectal excision technique-past, present, and future. Clin Colon Rectal Surg 2020; 33 (03) 134-143
- 16 Lin M, Chen W, Huang L, Ni J, Ding W, Yin L. The anatomic basis of total mesorectal excision. Am J Surg 2011; 201 (04) 537-543
- 17 Zeng Z, Luo S, Zhang H. et al; Chinese Transanal Endoscopic Surgery Collaborative (CTESC) Group. Transanal vs laparoscopic total mesorectal excision and 3-year disease-free survival in rectal cancer: The TaLaR randomized clinical trial. JAMA 2025; 333 (09) 774-783
- 18 Vennix S, Pelzers L, Bouvy N. et al. Laparoscopic versus open total mesorectal excision for rectal cancer. Cochrane Database Syst Rev 2014; 2014 (04) CD005200
- 19 Bahadoer RR, Dijkstra EA, van Etten B. et al; RAPIDO collaborative investigators. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): A randomised, open-label, phase 3 trial. Lancet Oncol 2021; 22 (01) 29-42
- 20 Conroy T, Bosset JF, Etienne PL. et al; Unicancer Gastrointestinal Group and Partenariat de Recherche en Oncologie Digestive (PRODIGE) Group. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): A multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2021; 22 (05) 702-715
- 21 Habr-Gama A, Perez RO, Nadalin W. et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: Long-term results. Ann Surg 2004; 240 (04) 711-717 , discussion 717–718
- 22 Dattani M, Heald RJ, Goussous G. et al. Oncological and survival outcomes in watch and wait patients with a clinical complete response after neoadjuvant chemoradiotherapy for rectal cancer: A systematic review and pooled analysis. Ann Surg 2018; 268 (06) 955-967
- 23 van der Valk MJM, Hilling DE, Bastiaannet E. et al; IWWD Consortium. Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): An international multicentre registry study. Lancet 2018; 391 (10139): 2537-2545
- 24 Loria A, Tejani MA, Temple LK. et al. Practice patterns for organ preservation in US patients with rectal cancer, 2006-2020. JAMA Oncol 2024; 10 (01) 79-86
- 25 Al-Najami I, Jones HJ, Dickson EA. et al. Rectal cancer: Watch-and-wait and continuing the rectal-preserving strategy with local excision for incomplete response or limited regrowth. Surg Oncol 2021; 37: 101574
- 26 Parfitt JR, Driman DK. The total mesorectal excision specimen for rectal cancer: A review of its pathological assessment. J Clin Pathol 2007; 60 (08) 849-855
- 27 Reynolds JV, Joyce WP, Dolan J, Sheahan K, Hyland JM. Pathological evidence in support of total mesorectal excision in the management of rectal cancer. Br J Surg 1996; 83 (08) 1112-1115
- 28 Wasmuth HH, Gachabayov M, Bokey L. et al. Statistical, clinical, methodological evaluation of local recurrence following transanal total mesorectal excision for rectal cancer: A systematic review. Dis Colon Rectum 2021; 64 (07) 899-914
- 29 Pennings AJ, Kimman ML, Gielen AHC, Beets GL, Melenhorst J, Breukink SO. Burden of disease experienced by patients following a watch-and-wait policy for locally advanced rectal cancer: A qualitative study. Colorectal Dis 2021; 23 (11) 2870-2878
- 30 Vermeer TA, Orsini RG, Daams F, Nieuwenhuijzen GA, Rutten HJ. Anastomotic leakage and presacral abscess formation after locally advanced rectal cancer surgery: Incidence, risk factors and treatment. Eur J Surg Oncol 2014; 40 (11) 1502-1509
- 31 Tooley JE, Sceats LA, Bohl DD, Read B, Kin C. Frequency and timing of short-term complications following abdominoperineal resection. J Surg Res 2018; 231: 69-76
- 32 Paun BC, Cassie S, MacLean AR, Dixon E, Buie WD. Postoperative complications following surgery for rectal cancer. Ann Surg 2010; 251 (05) 807-818
- 33 Saadat LV, Fields AC, Lyu H. et al. National Surgical Quality Improvement Program analysis of unplanned reoperation in patients undergoing low anterior resection or abdominoperineal resection for rectal cancer. Surgery 2019; 165 (03) 602-607
- 34 How P, Stelzner S, Branagan G. et al. Comparative quality of life in patients following abdominoperineal excision and low anterior resection for low rectal cancer. Dis Colon Rectum 2012; 55 (04) 400-406
- 35 Koëter T, Bonhof CS, Schoormans D. et al. Long-term outcomes after surgery involving the pelvic floor in rectal cancer: Physical activity, quality of life, and health status. J Gastrointest Surg 2019; 23 (04) 808-817
- 36 Konanz J, Herrle F, Weiss C, Post S, Kienle P. Quality of life of patients after low anterior, intersphincteric, and abdominoperineal resection for rectal cancer–a matched-pair analysis. Int J Colorectal Dis 2013; 28 (05) 679-688
- 37 Russell MM, Ganz PA, Lopa S. et al. Comparative effectiveness of sphincter-sparing surgery versus abdominoperineal resection in rectal cancer: Patient-reported outcomes in National Surgical Adjuvant Breast and Bowel Project randomized trial R-04. Ann Surg 2015; 261 (01) 144-148
- 38 Feddern ML, Emmertsen KJ, Laurberg S. Quality of life with or without sphincter preservation for rectal cancer. Colorectal Dis 2019; 21 (09) 1051-1057
- 39 Pieniowski EHA, Palmer GJ, Juul T. et al. Low anterior resection syndrome and quality of life after sphincter-sparing rectal cancer surgery: A long-term longitudinal follow-up. Dis Colon Rectum 2019; 62 (01) 14-20
- 40 Borstlap WAA, Westerduin E, Aukema TS, Bemelman WA, Tanis PJ. Dutch Snapshot Research Group. Anastomotic leakage and chronic presacral sinus formation after low anterior resection: Results from a large cross-sectional study. Ann Surg 2017; 266 (05) 870-877
- 41 Snijders HS, Wouters MW, van Leersum NJ. et al. Meta-analysis of the risk for anastomotic leakage, the postoperative mortality caused by leakage in relation to the overall postoperative mortality. Eur J Surg Oncol 2012; 38 (11) 1013-1019
- 42 Hain E, Manceau G, Maggiori L, Mongin C, Prost À la Denise J, Panis Y. Bowel dysfunction after anastomotic leakage in laparoscopic sphincter-saving operative intervention for rectal cancer: A case-matched study in 46 patients using the Low Anterior Resection Score. Surgery 2017; 161 (04) 1028-1039
- 43 Ashburn JH, Stocchi L, Kiran RP, Dietz DW, Remzi FH. Consequences of anastomotic leak after restorative proctectomy for cancer: Effect on long-term function and quality of life. Dis Colon Rectum 2013; 56 (03) 275-280
- 44 Lee SY, Kim CH, Kim YJ, Kim HR. Anastomotic stricture after ultralow anterior resection or intersphincteric resection for very low-lying rectal cancer. Surg Endosc 2018; 32 (02) 660-666
- 45 Marinatou A, Theodoropoulos GE, Karanika S. et al. Do anastomotic leaks impair postoperative health-related quality of life after rectal cancer surgery? A case-matched study. Dis Colon Rectum 2014; 57 (02) 158-166
- 46 Mongin C, Maggiori L, Agostini J, Ferron M, Panis Y. Does anastomotic leakage impair functional results and quality of life after laparoscopic sphincter-saving total mesorectal excision for rectal cancer? A case-matched study. Int J Colorectal Dis 2014; 29 (04) 459-467
- 47 Liu L, Herrinton LJ, Hornbrook MC, Wendel CS, Grant M, Krouse RS. Early and late complications among long-term colorectal cancer survivors with ostomy or anastomosis. Dis Colon Rectum 2010; 53 (02) 200-212
- 48 Nastro P, Knowles CH, McGrath A, Heyman B, Porrett TR, Lunniss PJ. Complications of intestinal stomas. Br J Surg 2010; 97 (12) 1885-1889
- 49 Marinez AC, González E, Holm K. et al. Stoma-related symptoms in patients operated for rectal cancer with abdominoperineal excision. Int J Colorectal Dis 2016; 31 (03) 635-641
- 50 Song L, Han X, Zhang J, Tang L. Body image mediates the effect of stoma status on psychological distress and quality of life in patients with colorectal cancer. Psychooncology 2020; 29 (04) 796-802
- 51 Hawkins AT, Berger DL, Shellito PC, Sylla P, Bordeianou L. Wound dehiscence after abdominoperineal resection for low rectal cancer is associated with decreased survival. Dis Colon Rectum 2014; 57 (02) 143-150
- 52 Welsch T, Mategakis V, Contin P, Kulu Y, Büchler MW, Ulrich A. Results of extralevator abdominoperineal resection for low rectal cancer including quality of life and long-term wound complications. Int J Colorectal Dis 2013; 28 (04) 503-510
- 53 Asplund D, Prytz M, Bock D, Haglind E, Angenete E. Persistent perineal morbidity is common following abdominoperineal excision for rectal cancer. Int J Colorectal Dis 2015; 30 (11) 1563-1570
- 54 Björklund Sand L, Gronkvist R, Haglind E, Angenete E. Persistent sitting and walking difficulties after abdominoperineal excision and anterior resection: Results from the Quality of Life in Rectal Cancer (QoLiRECT) Study. Dis Colon Rectum 2025; 68: 704-712
- 55 Colov EP, Klein M, Gögenur I. Wound complications and perineal pain after extralevator versus standard abdominoperineal excision: A nationwide study. Dis Colon Rectum 2016; 59 (09) 813-821
- 56 Maas CP, Moriya Y, Steup WH, Klein Kranenbarg E, van de Velde CJ. A prospective study on radical and nerve-preserving surgery for rectal cancer in the Netherlands. Eur J Surg Oncol 2000; 26 (08) 751-757
- 57 Nesbakken A, Nygaard K, Bull-Njaa T, Carlsen E, Eri LM. Bladder and sexual dysfunction after mesorectal excision for rectal cancer. Br J Surg 2000; 87 (02) 206-210
- 58 Lange MM, Marijnen CA, Maas CP. et al; Cooperative clinical investigators of the Dutch. Risk factors for sexual dysfunction after rectal cancer treatment. Eur J Cancer 2009; 45 (09) 1578-1588
- 59 Kim NK, Aahn TW, Park JK. et al. Assessment of sexual and voiding function after total mesorectal excision with pelvic autonomic nerve preservation in males with rectal cancer. Dis Colon Rectum 2002; 45 (09) 1178-1185
- 60 Torrijo I, Balciscueta Z, Tabet J, Martín MC, López M, Uribe N. Prospective study of sexual function and analysis of risk factors after rectal cancer surgery. Colorectal Dis 2021; 23 (06) 1379-1392
- 61 Numata M, Yamaguchi T, Shiomi A. et al; LANDMARC Collaborative Study Group of the Japan Society of Laparoscopic Colorectal Surgery. Prospective multicenter comprehensive survey on male sexual dysfunction following Laparoscopic, Robotic, and Transanal Approaches for Rectal Cancer (the LANDMARC Study). Ann Surg 2024; (e-pub ahead of print)
- 62 Breukink SO, van der Zaag-Loonen HJ, Bouma EM. et al. Prospective evaluation of quality of life and sexual functioning after laparoscopic total mesorectal excision. Dis Colon Rectum 2007; 50 (02) 147-155
- 63 Dijkstra EA, Nilsson PJ, Hospers GAP. et al; Collaborative Investigators. Locoregional failure during and after short-course radiotherapy followed by chemotherapy and surgery compared with long-course chemoradiotherapy and surgery: A 5-year follow-up of the RAPIDO trial. Ann Surg 2023; 278 (04) e766-e772
- 64 Thyø A, Elfeki H, Laurberg S, Emmertsen KJ. Female sexual problems after treatment for colorectal cancer - a population-based study. Colorectal Dis 2019; 21 (10) 1130-1139
- 65 van der Sande ME, Hupkens BJP, Berbée M. et al. Impact of radiotherapy on anorectal function in patients with rectal cancer following a watch and wait programme. Radiother Oncol 2019; 132: 79-84
- 66 Kneist W, Junginger T. Long-term urinary dysfunction after mesorectal excision: A prospective study with intraoperative electrophysiological confirmation of nerve preservation. Eur J Surg Oncol 2007; 33 (09) 1068-1074
- 67 El-Shami K, Oeffinger KC, Erb NL. et al. American Cancer Society Colorectal Cancer Survivorship Care Guidelines. CA Cancer J Clin 2015; 65 (06) 428-455
- 68 Custers PA, van der Sande ME, Grotenhuis BA. et al; Dutch Watch-and-Wait Consortium. Long-term quality of life and functional outcome of patients with rectal cancer following a watch-and-wait approach. JAMA Surg 2023; 158 (05) e230146
- 69 Hupkens BJP, Martens MH, Stoot JH. et al. Quality of life in rectal cancer patients after chemoradiation: Watch-and-wait policy versus standard resection - A matched-controlled study. Dis Colon Rectum 2017; 60 (10) 1032-1040
- 70 Quezada-Diaz FF, Smith JJ, Jimenez-Rodriguez RM. et al. Patient-reported bowel function in patients with rectal cancer managed by a watch-and-wait strategy after neoadjuvant therapy: A case-control study. Dis Colon Rectum 2020; 63 (07) 897-902
- 71 van der Sande ME, Figueiredo N, Beets GL. Management and outcome of local regrowths in a watch-and-wait prospective cohort for complete responses in rectal cancer. Ann Surg 2021; 274 (06) e1056-e1062
- 72 Glynne-Jones R, Hughes R. Critical appraisal of the ‘wait and see’ approach in rectal cancer for clinical complete responders after chemoradiation. Br J Surg 2012; 99 (07) 897-909
- 73 Fernandez LM, São Julião GP, Santacruz CC. et al. Risks of organ preservation in rectal cancer: Data from two international registries on rectal cancer. J Clin Oncol 2025; 43: 1663-1672
- 74 Socha J, Bujko K. The ultimate local failure rate after the watch-and-wait strategy for rectal cancer: a systematic review of literature and meta-analysis. Acta Oncol 2023; 62 (09) 1052-1065
- 75 Bhutiani N, Ochiai K, Peacock O. et al. Risk factors for regrowth after nonoperative management for rectal cancer. Ann Surg Oncol 2025; 32 (05) 3098-3105
- 76 Eastham JA, Auffenberg GB, Barocas DA. et al. Clinically localized prostate cancer: AUA/ASTRO Guideline, Part II: Principles of active surveillance, principles of surgery, and follow-up. J Urol 2022; 208 (01) 19-25
- 77 McCaughan D, Roman E, Sheridan R. et al. Patient perspectives of ‘Watch and Wait’ for chronic haematological cancers: Findings from a qualitative study. Eur J Oncol Nurs 2023; 65: 102349
- 78 Hilty Chu BK, Loria A, Dhimal T. et al. Challenges of surveillance in implementing nonoperative management for rectal cancer. JAMA Netw Open 2024; 7 (12) e2448682
- 79 Bulens PP, Smets L, Debucquoy A. et al. Nonoperative versus operative approach according to the response to neoadjuvant chemoradiotherapy for rectal cancer: A prospective cohort study. Clin Transl Radiat Oncol 2022; 36: 113-120
- 80 Chiloiro G, Meldolesi E, Giraffa M. et al. Could the conservative approach be considered safe in the treatment of locally advanced rectal cancer in case of a clinical near-complete or complete response? A retrospective analysis. Clin Transl Radiat Oncol 2021; 28: 1-9
- 81 Coronado-Vázquez V, Canet-Fajas C, Delgado-Marroquín MT, Magallón-Botaya R, Romero-Martín M, Gómez-Salgado J. Interventions to facilitate shared decision-making using decision aids with patients in primary health care: A systematic review. Medicine (Baltimore) 2020; 99 (32) e21389
- 82 Bruch JD, Khazen M, Mahmic-Kaknjo M, Légaré F, Ellen ME. The effects of shared decision making on health outcomes, health care quality, cost, and consultation time: An umbrella review. Patient Educ Couns 2024; 129: 108408
- 83 Wu RC, Boushey RP, Scheer AS. et al. Evaluation of the rectal cancer patient decision aid: A before and after study. Dis Colon Rectum 2016; 59 (03) 165-172
- 84 Smets L, Debucquoy A, Oldenburger E. et al. Development of a patient decision aid for rectal cancer patients with clinical complete response after neo-adjuvant treatment. Cancers (Basel) 2023; 15 (03) 806
- 85 Jaeken J, Billiouw C, Mertens L. et al. A systematic review of shared decision making training programs for general practitioners. BMC Med Educ 2024; 24 (01) 592
- 86 Chapman BC, Lai SH, Friedrich T. et al. Rectal cancer: Clinical and molecular predictors of a complete response to total neoadjuvant therapy. Dis Colon Rectum 2023; 66 (04) 521-530
- 87 Yilmaz S, Liska D, Conces ML. et al. What predicts complete response to total neoadjuvant therapy in locally advanced rectal cancer?. Dis Colon Rectum 2025; 68 (01) 60-68
- 88 Sacks GD, Dawes AJ, Tsugawa Y. et al. The association between risk aversion of surgeons and their clinical decision-making. J Surg Res 2021; 268: 232-243
- 89 Veilleux S, Noiseux I, Lachapelle N. et al; iGenoMed Consortium. Patients' perception of their involvement in shared treatment decision making: Key factors in the treatment of inflammatory bowel disease. Patient Educ Couns 2018; 101 (02) 331-339
- 90 Shay LA, Lafata JE. Where is the evidence? A systematic review of shared decision making and patient outcomes. Med Decis Making 2015; 35 (01) 114-131
- 91 Sahni NR, Carrus B. Artificial intelligence in U.S. health care delivery. N Engl J Med 2023; 389 (04) 348-358
- 92 Yang Y, Zhao Y, Liu X, Huang J. Artificial intelligence for prediction of response to cancer immunotherapy. Semin Cancer Biol 2022; 87: 137-147
- 93 Carrasco-Ribelles LA, Llanes-Jurado J, Gallego-Moll C. et al. Prediction models using artificial intelligence and longitudinal data from electronic health records: A systematic methodological review. J Am Med Inform Assoc 2023; 30 (12) 2072-2082